Drug: Fulphila (pegfilgrastim-jmdb)

Manufacturer: Biocon Biologics

Route of Administration: Subcutaneous

Site of Care: Outpatient

Approved Indication: to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of febrile neutropenia

Disease: neutropenia associated with myelosuppressive anti-cancer therapy

Therapeutic Area: Hematology, Oncology

Enrollment Form Link: My Biocon Biologics

Phone Number: 1-833-695-2623

Fax Number: 833-247-2756

Product Website: fulphila.com